Frevecitinib Drug Asset Due Diligence Report 2026

This Frevecitinib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Frevecitinib can convert its Small molecule drug profile and JAK1 x JAK2 x JAK3 x TRPV1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Frevecitinib (query alias: Frevecitinib)
Modality / target	Small molecule drug; JAK1 x JAK2 x JAK3 x TRPV1; JAK1 inhibitors, JAK2 inhibitors, JAK3 inhibitors
Highest global status	Phase 2
Originator	Vectura Group Ltd.
Active developers	Kinaset Therapeutics, Inc.

The MCP disease footprint includes Severe asthma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07532265	Phase 2	Recruiting	512	Primary endpoint not disclosed in English source
NCT05006521	Phase 1	Completed	117	Primary endpoint not disclosed in English source
NCT02740049	Early Phase 1	Completed	9	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Inhaled Frevecitinib Reduces Sputum Eosinophils and Improves FEV1and ACQ-6 in Subjects With Moderate to Severe Asthma Treated With ICS/LABA

Phase 3; n=23; evaluation: Positive. Reported fields: ACQ-6 = -0.15 Point ; ACQ-6 reduction = 33 %

Safety and PK of KN-002 in subjects with moderate to severe asthma using ICS/LABA

Phase 1; n=23; evaluation: Positive. Reported fields: AE(Headache) = 3.0 Pts ; AE(Headache) = 1.0 Pts

Late Breaking Abstract - The safety and PK of an inhaled pan JAK inhibitor (KN-002) in subjects with COPD

Phase 1; n=13; evaluation: Positive. Reported fields: AE(The most common AE was headache) = 2.0 Pts ; AE(The most common AE was headache) = 1.0 Pts

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Frevecitinib addresses Severe asthma. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 1 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2020-11-30	Kinaset Therapeutics partners with Vectura to globally develop and commercialize VR-588 for asthma treatment.	Discovery	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Crystalline form of a JAK3 kinase inhibitor”. The milestone feed surfaced a patent-application signal described as “Novel polymorphs”. The milestone feed surfaced a patent-application signal described as “N-containing heteroaryl derivatives as JAK3 kinase inhibitors”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO